Alternatively, targeting tumor-associated macrophages could be explored to abrogate the negative effects of GLP-1 targeting agents.34 In conclusion, this study unveils a critical clinical scenario that may significantly impact survival outcomes in an aggressive cancer, highlighting the imperative to more carefully assess how metabolic therapies impinge on cancer treatments. This evidence concerns the gene GLP1R and cancer.